Makers Laboratories

Makers Laboratories EBITDA per Share

The EBITDA per Share of Makers Laboratories (506919.BO) as of Oct 22, 2026 is 19.85 INR. In the previous year, EBITDA per Share was 13.22 INR — a change of 50.17% (higher).

EBITDA per Share

19.85INR

YoY

50.17%

Last updated:

EBITDA per Share of Makers Laboratories is 2026 19.85 INR. EBITDA per Share of Makers Laboratories was 2025 13.22 INR. It decreases by 50.17% higher compared to the previous year.

The Makers Laboratories EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
7.42 INR
Jan 1, 2020
5.29 INR
Jan 1, 2021
14.05 INR
Jan 1, 2022
35.08 INR
Jan 1, 2023
9.36 INR
Jan 1, 2024
4.37 INR
Jan 1, 2025
13.22 INR
Jan 1, 2026
19.85 INR
The Makers Laboratories EBITDA per Share history
YEAREBITDA per ShareYoY
19.85INR+50.17%
13.22INR+202.21%
4.37INR-53.27%
9.36INR-73.31%
35.08INR+149.69%
14.05INR+165.63%
5.29INR-28.69%
7.42INR-2.57%
7.61INR-30.50%
10.95INR+38.51%
7.91INR+6.90%
7.40INR+74.72%
4.23INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Makers Laboratories Stock analysis

What does Makers Laboratories do? Makers Laboratories Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across various therapeutic segments. The company's product portfolio includes formulation brands such as Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (anti-cough range), and Exylin (Amoxycillin range). These brands target general health needs and are distributed through the Inspira retail packs division, which covers categories like acid regulatory, anthelmintics, anti-allergics, and anti-hypertensives. The Experia bulk packs division supplies bulk pharmaceutical products including amoxycillin 250 mg capsules and chloroquine phosphate 250 mg tablets to healthcare providers and pharmacies. The company's primary customers are healthcare providers and pharmacies that purchase its formulation brands and bulk packs for resale or direct patient use. The Inspira retail packs division serves retail consumers seeking over-the-counter medications for common ailments, while the Experia bulk packs division caters to institutional buyers needing bulk quantities for distribution. Makers Laboratories Ltd. focuses on the pharmaceuticals segment, offering products that address diverse health conditions through its established brand portfolio. Revenue streams are derived from both retail and bulk sales, with formulation brands driving consumer-facing sales and bulk packs supporting institutional distribution. The company's product range spans multiple therapeutic areas, ensuring consistent demand across different healthcare segments. By maintaining a diverse portfolio of branded and bulk pharmaceutical products, Makers Laboratories Ltd. effectively targets both end consumers and healthcare institutions within the Indian pharmaceutical market. Makers Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Makers Laboratories stock

EBITDA per Share of Makers Laboratories is 19.85 INR in 2026.

EBITDA per Share of Makers Laboratories changed from 13.22 INR to 19.85 INR, representing a 50.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Makers Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Makers Laboratories

All Key Metrics — Makers Laboratories